Share
clock Created with Sketch. 28/10/14
08:24
Share
Originally posted by lilypily
↑
Correct but no point having the safest drug in the world if it has no efficacy - safety is pretty much a given - no dropouts and at AGM , numerous FDA meetings re safety had nothing to report. Secondary endpoints are the key. Going from the medical journal of FB there are compelling stories - but unfortunately at the moment they are just that. In saying that with an A-grade management team , strong trial design and numerous measurable secondary endpoints I'm quietly confident. We hav a lot of the right boxes ticked vs the other failed biotechs. Can't really compare them and there failures.
Expand
There is also the outside validation from US ARMY... 4 phase 2 trials with the US ARMY says a lot about the science...
(20min delay)